Previous 10 | Next 10 |
The FDA has accepted Exelixis' (NASDAQ:EXEL) supplemental New Drug Application (sNDA) for CABOMETYX (cabozantinib) as a treatment for patients 12 years and older with differentiated thyroid cancer (DTC) who have progressed following prior therapy and are radioactive iodine-refractory. Th...
– U.S. Food and Drug Administration assigned a Prescription Drug User Fee Act action date of December 4, 2021 – – The supplemental New Drug Application is based on the phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in pr...
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2021 financial results will be released on Thursday, August 5, 2021 after the markets close. At 5:00 p.m. EDT / ...
Shares of Exelixis Inc. (NASDAQ:EXEL) traded at a new 52-week low today of $16.51. This new low was reached on below average trading volume as 1.4 million shares traded hands, while the average 30-day volume is approximately 2.8 million shares. Exelixis Inc is a biopharmaceutical firm th...
Shares of Exelixis Inc. (NASDAQ:EXEL) traded today at $16.86, breaking its 52-week low. This new low was reached on below average trading volume as 1.4 million shares traded hands, while the average 30-day volume is approximately 2.7 million shares. In the past 52 weeks, shares of Exelix...
Shares of Exelixis Inc. (NASDAQ:EXEL) traded today at $17.46, breaking its 52-week low. So far today approximately 1.4 million shares have been exchanged, as compared to an average 30-day volume of 2.7 million shares. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and...
On June 28, shareholders in the cancer therapeutics company Exelixis (NASDAQ: EXEL) got a nasty shock: Its stock price plunged by more than 23% after it delivered worse-than-expected data from a phase 3 clinical trial. The company's flagship renal cell carcinoma drug, Cabometyx, was...
Exelixis (NASDAQ: EXEL) recently reported bad news from a late-stage study evaluating a combination of Cabometyx with Tecentriq in treating liver cancer. The biotech stock immediately sank close to 20%. In this Motley Fool Live video recorded on June 30, 2021 , Motley F...
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the company’s Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual Wil...
Shares of Exelixis Inc. (NASDAQ:EXEL) traded at a new 52-week low today of $17.61. Approximately 1.4 million shares have changed hands today, as compared to an average 30-day volume of 2.7 million shares. In the past 52 weeks, shares of Exelixis Inc. have traded between the current low o...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...